Skip to NavigationSkip to content

Recipharm appoints Hans Lennernäs to operating Board

Published on: 05/02/13

Recipharm Pharmaceutical Development AB has announced the appointment of Dr Hans Lennernäs to the company’s Board of directors.

Lennernäs is a Professor of Biopharmaceutics at Uppsala University. He currently manages an IMI project entitled OrBiTo, which aims to improve oral drug delivery.

Lennernäs has served as the principal investigator in an extensive collaboration with the FDA, University of Michigan, US, and Medical Product Agency, Sweden over the course of  several years in which he developed a new guideline for the Biopharmaceutics Classification System.

In addition to his academic achievements, Dr Lennernäs  has built an entrepreneurial reputation  by cofounding  several companies including DuoCort Pharma AB, and LIDDS AB, whilst investing in a number of patents.

“I am very much looking forward to serving on the Board of directors at Recipharm Pharmaceutical Development AB,” Lennernäs commented.

“We are very pleased to welcome a Board member of Hans Lennernäs calibre,” remarked general manager Maria Lundberg.

“His track record of successfully inventing and developing several novel drug delivery systems that are currently in pre-clinical phase and in preparation for Phase I, II and III clinical trials, makes him an excellent addition to the Board.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches